KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Gains from Investment Securities (2019 - 2025)

Boston Scientific (BSX) has disclosed Gains from Investment Securities for 9 consecutive years, with $247.0 million as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 1173.91% to $247.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $289.0 million through Dec 2025, up 1170.37% year-over-year, with the annual reading at $258.0 million for FY2025, 1221.74% up from the prior year.
  • Gains from Investment Securities hit $247.0 million in Q4 2025 for Boston Scientific, up from $11.0 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $247.0 million in Q4 2025 to a low of -$85.0 million in Q2 2021.
  • Historically, Gains from Investment Securities has averaged $15.1 million across 5 years, with a median of $12.0 million in 2022.
  • Biggest five-year swings in Gains from Investment Securities: plummeted 533.33% in 2021 and later soared 1173.91% in 2025.
  • Year by year, Gains from Investment Securities stood at $35.0 million in 2021, then skyrocketed by 54.29% to $54.0 million in 2022, then crashed by 179.63% to -$43.0 million in 2023, then soared by 46.51% to -$23.0 million in 2024, then skyrocketed by 1173.91% to $247.0 million in 2025.
  • Business Quant data shows Gains from Investment Securities for BSX at $247.0 million in Q4 2025, $11.0 million in Q3 2025, and -$5.0 million in Q2 2025.